Suppr超能文献

人脂肪细胞中利钠肽依赖性脂解途径的功能和药理学特征

Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells.

作者信息

Moro Cedric, Galitzky Jean, Sengenes Coralie, Crampes François, Lafontan Max, Berlan Michel

机构信息

Unité de recherches sur les obésités, Institut National de la Santé et de la Recherche Médicale, Universitaire Rangueil, Toulouse, France.

出版信息

J Pharmacol Exp Ther. 2004 Mar;308(3):984-92. doi: 10.1124/jpet.103.060913. Epub 2003 Nov 21.

Abstract

A lipolytic pathway involving natriuretic peptides has recently been discovered in human fat cells. Its functional characteristics and the interactions of the atrial natriuretic peptide (ANP)-induced effects with adrenergic and insulin pathways were studied. Characterization of the action of ANP antagonists, i.e., A71915, anantin, S-28-Y (Ser-28-Tyr, a synthesized peptide), and HS-142-1 (a microbial polysaccharide), was performed. Lipolytic assays and intracellular cGMP and cAMP determinations were performed on isolated fat cells. Cell membranes were used for binding studies. At low concentrations ANP and isoproterenol [beta-adrenergic receptor (beta-AR) agonist] exerted additive lipolytic effects. The alpha(2)-AR pathway did not interfere with that of ANP. Lipolytic effects of ANP were unaltered by a 2-h pretreatment of fat cells with insulin, whereas beta-AR-induced lipolysis was reduced. Homologous desensitization occurred for ANP-dependent lipolytic pathways. Dendroapsis natriuretic peptide exhibited a similar maximal effect but a 10-fold higher lipolytic potency than ANP and mini-ANP (the shortest form of ANP). The antagonist A71915 exhibited competitive antagonistic properties with a pA(2) value of 7.51. Anantin displayed noncompetitive antagonism and exerted an inhibitory action on basal and beta-adrenergic receptor-induced lipolytic response. S-28-Y exhibited antagonist potencies toward ANP-induced lipolysis and behaved as a partial lipolytic agonist with a lower pD(2) value (7.4 +/- 0.2) than ANP (9.4 +/- 0.3). HS-142-1 exerted the weakest antagonistic effects. The results demonstrate that ANP-dependent effects do not interfere with beta- and alpha(2)-adrenergic pathways in human fat cells. They are unaffected by insulin pretreatments of fat cells but undergo desensitization. In the search of potent and specific natriuretic peptide receptor-A antagonist, in the human fat cell, A71915 was the only reliable one found.

摘要

最近在人体脂肪细胞中发现了一条涉及利钠肽的脂解途径。对其功能特性以及心房利钠肽(ANP)诱导的效应与肾上腺素能和胰岛素途径之间的相互作用进行了研究。对ANP拮抗剂,即A71915、蛙皮素、S - 28 - Y(Ser - 28 - Tyr,一种合成肽)和HS - 142 - 1(一种微生物多糖)的作用进行了表征。对分离的脂肪细胞进行了脂解测定以及细胞内cGMP和cAMP测定。使用细胞膜进行结合研究。在低浓度下,ANP和异丙肾上腺素[β - 肾上腺素能受体(β - AR)激动剂]发挥相加的脂解作用。α₂ - AR途径不干扰ANP途径。用胰岛素对脂肪细胞进行2小时预处理后,ANP的脂解作用未改变,而β - AR诱导的脂解作用减弱。ANP依赖性脂解途径发生同源脱敏。树眼镜蛇利钠肽表现出类似的最大效应,但脂解效力比ANP和微型ANP(ANP的最短形式)高10倍。拮抗剂A71915表现出竞争性拮抗特性,pA₂值为7.51。蛙皮素表现出非竞争性拮抗作用,并对基础和β - 肾上腺素能受体诱导的脂解反应发挥抑制作用。S - 28 - Y对ANP诱导的脂解表现出拮抗效力,并表现为部分脂解激动剂,其pD₂值(7.4±0.2)低于ANP(9.4±0.3)。HS - 142 - 1发挥的拮抗作用最弱。结果表明,ANP依赖性效应不干扰人体脂肪细胞中的β - 和α₂ - 肾上腺素能途径。它们不受脂肪细胞胰岛素预处理的影响,但会发生脱敏。在寻找强效和特异性利钠肽受体 - A拮抗剂的过程中,在人体脂肪细胞中,A71915是唯一发现的可靠拮抗剂。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验